Supplementary Figure 4 from Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs
Abstract
Supplementary Figure 4. Metformin promotes upregulation of COX2 in 4NQO carcinogen-induced oral premalignant lesions. (Related to Figure 3)
Fields of Study & Subjects
Metabolism
Diabetes
and Cancer
Cancer
Hypoxia
and Metabolism
Head and Neck Cancer Studies
Publication details
- Publication date
- 6 February 2026